Compare Adaptive Biotechnologies Corp (ADPT) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs GoPro Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.12 (market cap $4.04B), while GoPro Inc trades at $0.6 (market cap $114.41M). The key difference: Adaptive Biotechnologies Corp is far larger — about 35.3× GoPro Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | GPRO | |
|---|---|---|
Market Cap | $4.04B | $114.41M |
Sector | Health | Technology |
52-Week High | $25.45 | $2.88 |
52-Week Low | $12.30 | $0.62 |
Enterprise Value | $4.10B | $173.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
GoPro (GPRO) trades at $0.70, down 3.53% in the last 24 hours, reflecting ongoing financial distress with a net income margin of -28.52% and negative cash flow. The stock is technically bearish, with moving averages signaling sell pressure, while recent news highlights a strategic review for a potential sale. Revenue has declined from $1.1B in 2022 to $652M in 2025, with consistent earnings misses and negative equity of -$681.61M.
The outlook hinges on the outcome of the strategic sale process, offering speculative upside if a buyer emerges, but risks include persistent cash burn, competitive pressures, and weak sales trends. Analysts are cautious, with only 21.43% recommending buy, as the company faces going-concern risks and dilution from financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
